Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

BACKGROUND: Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma patients. METHODS: We conducted a phase I/II study of the EGFR inhibitor erlotinib (150 mg/day) and the mTOR inhibitor temsirol...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Wen, Patrick Y., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Norden, Andrew D., Cloughesy, Timothy F., Robins, H. Ian, Lieberman, Frank S., Gilbert, Mark R., Mehta, Minesh P., Drappatz, Jan, Groves, Morris D., Santagata, Sandro, Ligon, Azra H., Yung, W.K. Alfred, Wright, John J., Dancey, Janet, Aldape, Kenneth D., Prados, Michael D., Ligon, Keith L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2014
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956354/
https://ncbi.nlm.nih.gov/pubmed/24470557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not247
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia